版本:
中国

BRIEF-Ligand enters OmniAb license agreement with TeneoBio inc

Sept 16 Ligand Pharmaceuticals Inc

* Ligand enters OmniAb license agreement with TeneoBio inc

* Under license, TeneoBio will be able to use OmniFlic technology from OmniAb platform

* TeneoBio will be responsible for all costs related to programs Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐